EUVIMEDObjevte EUVIMED
Open access

Expanding the therapeutic landscape of PDE10A inhibition through alchemical absolute binding free energy calculations and in‐vitro evaluation

Bhanu Sharma, Rahul Singh, Ashish Kumar, Pralay Das, Rituraj Purohit

Protein Science · 2026-02 · 35 (2)

DOI: 10.1002/pro.70472 ↗

At a glance

Journal article in Protein Science, published online on 2026-01-28. Written by Bhanu Sharma and 4 co-authors. Institution: Structural Bioinformatics Lab, Biotechnology Division, CSIR-Institute of Himalayan Bioresource Technology, Palampur, India. Major MEDLINE topics: Phosphoric Diester Hydrolases, Phosphodiesterase Inhibitors. Cited 26 times so far (Crossref); 39 references. The full text is freely available in PubMed Central. Funded by: Council of Scientific and Industrial Research, India.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

In preclinical models, Phosphodiesterase‐10A (PDE10A) inhibition has shown efficacy for Parkinson's and Huntington's diseases and is potentially a therapeutic approach for schizophrenia. In this study, computational approaches were employed to identify selective PDE10A inhibitors from a series of olefinated benzosuberene analogues. The molecular interactions and docking scores of the selected molecules were compared with three different co‐crystal inhibitors of PDE10A. Molecular dynamics (MD) simulations confirmed the stability of the screened hit molecules with PDE10A, and AMKPD‐52 was found to uniquely interact with the selectivity pocket residue Tyr‐683. Further refinement using steered MD simulations and umbrella sampling simulations with a total simulation time of ~72 μs reinforced AMKPD‐52 as the potential lead molecule. Absolute binding free energy calculations performed using multistate Bennett acceptance ratio method consistently ranked AMKPD‐52 as the potential lead molecule for PDE10A inhibition. Experimental evaluation revealed an IC₅₀ value of 11.52 μM for AMKPD‐52, confirming its inhibitory activity against PDE10A. Although the binding affinity and potency were modest compared to the reference inhibitor TAK‐063, the natural origin and straightforward synthetic tractability of AMKPD‐52 make it an attractive candidate for further medicinal chemistry optimization. These findings warrant in vivo validation to assess the therapeutic potential of AMKPD‐52 in PDE10A‐targeted interventions.

Subjects

MeSH terms (MEDLINE)

Phosphoric Diester HydrolasesPhosphodiesterase InhibitorsMolecular Dynamics SimulationProtein BindingHumans

Author keywords

PDE10Abenzosuberene analoguesmolecular dynamicsumbrella sampling

Substances

PDE10A protein, humanPhosphoric Diester HydrolasesPhosphodiesterase Inhibitors

Authors and institutions

  • Structural Bioinformatics Lab, Biotechnology Division, CSIR-Institute of Himalayan Bioresource Technology, Palampur, India.
  • Academy of Scientific and Innovative Research, Ghaziabad, India.
  • Chemical Technology Division, CSIR-Institute of Himalayan Bioresource Technology, Palampur, India.

Funding

  • Council of Scientific and Industrial Research, India

Cite

APA

Sharma, B., Singh, R., Kumar, A., Das, P., & Purohit, R. (2026). Expanding the therapeutic landscape of PDE10A inhibition through alchemical absolute binding free energy calculations and in‐vitro evaluation. Protein Science, 35(2). https://doi.org/10.1002/pro.70472

Vancouver

Sharma B, Singh R, Kumar A, Das P, Purohit R. Expanding the therapeutic landscape of PDE10A inhibition through alchemical absolute binding free energy calculations and in‐vitro evaluation. Protein Science. 2026;35(2). doi:10.1002/pro.70472

BibTeX
@article{Sharma2026,
  author = {Sharma, Bhanu and Singh, Rahul and Kumar, Ashish and Das, Pralay and Purohit, Rituraj},
  title = {Expanding the therapeutic landscape of PDE10A inhibition through alchemical absolute binding free energy calculations and in‐vitro evaluation},
  journal = {Protein Science},
  year = {2026},
  volume = {35},
  number = {2},
  doi = {10.1002/pro.70472}
}
Start for free →